MedPharm Ltd have announced the appointments of Dr Jon Lenn to the position of Chief Technology Officer (CTO) and Dr Haydn Sinclair to the role of Vice President of Pharmaceutical Quality with Global Responsibilities.
Jon Lenn, before being appointed CTO, was previously the SVP of US Operations where he led the creation and growth of MedPharm US subsidiary in RTP, North Carolina from its inception in 2016. Jon is well established as authority in pharmaceutical development of topical products having started his career in Connetics before having roles of increasing responsibility in Stiefel and GSK. In his new role, Jon will be focused on coordinating MedPharm’s technological innovation strategy particularly in the area of automation and performance testing to ensure MedPharm stays at the forefront of these scientific disciplines.
Haydn Sinclair is re-joining MedPharm to oversee all aspects of MedPharm’s quality system which encompasses both of MedPharm’s sites in North Carolina, USA and Guildford, UK. The capabilities of both sites are continuing to increase in parallel with MedPharm’s growth as an organisation. Haydn will be responsible for ensuring that the quality system remains at the high standard expected by MedPharm’s customers and is sufficiently flexible to accommodate the different requirements of formulation development, performance testing, and clinical manufacture. Additionally, Haydn will be responsible for maintaining all of MedPharm’s quality accreditations including GLP and cGMP.
“These two appointments reflect MedPharm’s desire to ensure we have the right people to lead all aspects of business as we continue to grow and offer more services to our clients”, comments Prof Marc Brown, MedPharm’s CSO and co-founder. “They show that MedPharm is developing as a global organisation.”
Notes to editors
Back to News
MedPharm is the world’s leading contract provider of topical and transdermal product design and formulation development services. MedPharm are experts at reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through their unique, cost-effective and industry-leading performance testing models. Well established as the global leaders in dermatology, nail, mucosal membrane, and transdermal product development, MedPharm can also offer innovative solutions for ophthalmic and airway preparations recognised for their scientific rigour by regulators and investors. MedPharm has fully established R&D centres in the USA and UK and has its global HQ in Guildford, UK.